Clinical Trials Logo

SHR-1210 clinical trials

View clinical trials related to SHR-1210.

Filter by:
  • None
  • Page 1

NCT ID: NCT04797507 Not yet recruiting - Anlotinib Clinical Trials

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Start date: March 2021
Phase: Phase 2
Study type: Interventional

This study was designed to explore the clinical efficacy of SHR-1210 in combined with Anlotinib in the treatment of second- or above- line advanced or metastatic esophageal squamous cell cancer patients, in order to find a better therapy strategy for esophageal squamous cell cancer patients.

NCT ID: NCT03986515 Recruiting - Advanced Cancer Clinical Trials

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Start date: June 4, 2019
Phase: Phase 2
Study type: Interventional

There is still no effective treatment for advanced mucosal melanoma at present. The efficacy of single-agent PD-1 inhibitors is less than 20%. It is urgent to explore regimens to improve the efficacy of PD-1 inhibitors in patients with advanced mucosal melanoma. This study is performed to explore the safety and efficacy of apatinib plus SHR-1210 in patients with advanced mucosa melanoma whose diseases progress after chemotherapy.